Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Kai Rejeski(Memorial Sloan Kettering Cancer Center), Ibrahim Yakoub‐Agha(Inserm), Matteo Giovanni Carrabba(Vita-Salute San Raffaele University), Julio Delgado(Departament de Salut), Roberta Di Blasi(Assistance Publique – Hôpitaux de Paris), Raffaella Greco(Vita-Salute San Raffaele University), Claire Roddie(Cancer Institute (WIA)), John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Fabio Ciceri(Vita-Salute San Raffaele University), Roch Houot(Inserm), Isabel Sánchez‐Ortega(European Society for Blood and Marrow Transplantation), Catherine Thiéblemont(Université Paris Cité), Marie José Kersten(Hovon), Ulrich Jäger(Medical University of Vienna), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Stephan Mielke(Karolinska University Hospital), Emmanuel Bachy(Université Claude Bernard Lyon 1), Paolo Corradini(Gruppo di Ricerca Geriatrica), Arnon Nagler(Sheba Medical Center), Pere Barba(Universitat Autònoma de Barcelona), Christian Chabannon(Inserm), Zinaida Perić(University of Rijeka), Francesco Onida(Peter MacCallum Cancer Centre), Fermín Sánchez‐Guijo(Universidad de Salamanca), Dominik Schneidawind(University Hospital of Zurich), John G. Gribben(Queen Mary University of London), Chiara Bonini(Vita-Salute San Raffaele University), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Annalisa Ruggeri(Inserm), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Max S. Topp(Universitätsklinikum Würzburg), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Maria‐Luisa Schubert(Heidelberg University), Marion Subklewe(LMU Klinikum), Reuben Benjamin(King's College London)
Cited by 330
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k